drugset / Trial / NCT00624026

Memantine - Communication Study

NCT00624026

Phase 3 Completed 107 enrolled Merz Pharmaceuticals GmbH
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study objective is to evaluate the effects of memantine treatment on communication abilities and other cognitive abilities in moderate to severe DAT patients.

Timeline

Start
2007-11
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg

Indications